The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Share News (GNS)

Share Price Information for Genus (GNS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,898.00
Bid: 1,898.00
Ask: 1,902.00
Change: 6.00 (0.32%)
Spread: 4.00 (0.211%)
Open: 1,852.00
High: 1,908.00
Low: 1,852.00
Prev. Close: 1,892.00
GNS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Genus shares plunge as expects adjusted profit and revenue decline

Thu, 15th Feb 2024 09:41

(Alliance News) - Genus PLC on Thursday warned that Chinese porcine markets continued to be "challenging", as it anticipates reporting lower revenue and adjusted pretax profit for its recent half-year.

Shares in the Basingstoke, England based animal genetics biotechnology company focused on cattle and pig farms plunged 30% to 1,478.00 pence each on Thursday morning in London.

Genus expects to report adjusted pretax profit for the financial first-half ended December 31 of GBP29 million on revenue of GBP334 million.

Both outcomes will be in line with expectations, but they would represent a 31% slump in adjusted pretax profit from GBP42.2 million a year before and a 4.6% decline on the top line from GBP350.2 million.

"[Pig Improvement Co] ex-China performed robustly, with North America, Latin America and Europe delivering adjusted operating profit growth in constant currency. China continues to be a challenging porcine market, however our enhanced commercial focus has resulted in winning new royalty customers in the period which will positively impact fiscal year 2025 and beyond," Genus added.

PIC sales comprise semen, embryos and breeding animals with 'superior' genetics to those animals currently on farms.

Genus said: "With regards to our PRP programme, recent engagement with the US Food & Drug Administration has shifted to the post-approval compliance procedures. This has clarified the data submissions and monitoring that will be required on an ongoing basis post-PRP approval. Validation of our procedures to comply with these monitoring requirements is expected to take several months. We therefore now expect FDA approval in fiscal year 2025. Our dialogue shifting to the post-approval compliance procedures reinforces our view that approval will be forthcoming. There are no changes to our commercialisation timeline or financial projections."

Genus's PRP programme focuses on pigs who are resistant to porcine reproductive and respiratory syndrome, or PRRS. Genus has developed a solution to protect pigs from the PRRS virus, which causes animal suffering and prematurely kills millions of pigs every year.

By Tom Budszus, Alliance News slot editor

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
28 Jun 2021 19:35

TRADING UPDATES: Anglo-Eastern tips palm oil price fall; DX expands

TRADING UPDATES: Anglo-Eastern tips palm oil price fall; DX expands

Read more
22 Jun 2021 20:34

IN BRIEF: Genus trial shows gene edited pigs resistant to PRRS virus

IN BRIEF: Genus trial shows gene edited pigs resistant to PRRS virus

Read more
22 Jun 2021 07:50

Genus provides update on PRRS virus resistance programme

(Sharecast News) - Animal genetics company Genus provided an update on its porcine reproductive and respiratory syndrome virus resistance programme as part of its capital markets event on Tuesday.

Read more
31 Mar 2021 17:13

DIRECTOR DEALINGS: Sealand Capital chair invests amid licence talks

DIRECTOR DEALINGS: Sealand Capital chair invests amid licence talks

Read more
31 Mar 2021 12:17

LONDON MARKET MIDDAY: Biden spends big; Deliveroo dives on debut

LONDON MARKET MIDDAY: Biden spends big; Deliveroo dives on debut

Read more
31 Mar 2021 09:37

BROKER RATINGS: BP cut by Morgan Stanley; Jefferies raises Hikma

BROKER RATINGS: BP cut by Morgan Stanley; Jefferies raises Hikma

Read more
25 Mar 2021 16:03

UK dividends calendar - next 7 days

UK dividends calendar - next 7 days

Read more
22 Mar 2021 14:07

IN BRIEF: Genus adds molecular biology head Jason Chin to board

IN BRIEF: Genus adds molecular biology head Jason Chin to board

Read more
26 Feb 2021 16:23

DIRECTOR DEALINGS: Hochschild, Wizz Air, Clipper Logistics Execs Sell

DIRECTOR DEALINGS: Hochschild, Wizz Air, Clipper Logistics Execs Sell

Read more
25 Feb 2021 17:04

LONDON MARKET CLOSE: Stocks Edge Lower As US Bond Yields Rise

LONDON MARKET CLOSE: Stocks Edge Lower As US Bond Yields Rise

Read more
25 Feb 2021 16:15

UK Dividends Calendar - Next 7 Days

UK Dividends Calendar - Next 7 Days

Read more
25 Feb 2021 13:49

Thursday broker round-up

(Sharecast News) - Medica Group: Liberum initiates at buy with a target price of 200p.

Read more
25 Feb 2021 12:04

LONDON MARKET MIDDAY: Stocks Notch Moderate Gains Ahead Of US Data

LONDON MARKET MIDDAY: Stocks Notch Moderate Gains Ahead Of US Data

Read more
25 Feb 2021 09:42

Genus Posts "Very Strong" Interim Results Despite Covid-19 Impact

Genus Posts "Very Strong" Interim Results Despite Covid-19 Impact

Read more
25 Feb 2021 09:33

BROKER RATINGS: AstraZeneca, Reckitt And Tesco Receive Upgrades

BROKER RATINGS: AstraZeneca, Reckitt And Tesco Receive Upgrades

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.